<SEC-DOCUMENT>0001193125-22-296533.txt : 20221201
<SEC-HEADER>0001193125-22-296533.hdr.sgml : 20221201
<ACCEPTANCE-DATETIME>20221201161354
ACCESSION NUMBER:		0001193125-22-296533
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221201
FILED AS OF DATE:		20221201
DATE AS OF CHANGE:		20221201

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-29962
		FILM NUMBER:		221438972

	BUSINESS ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		STATE:			C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d418328d6k.htm
<DESCRIPTION>FORM 6-K
<TEXT>
<HTML><HEAD>
<TITLE>Form 6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT
STYLE="white-space:nowrap">6-K</FONT> </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF
FOREIGN PRIVATE ISSUER </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR
<FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of December, 2022 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#146;s name into English) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three
International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form
20-F&nbsp;&nbsp;&nbsp;&#9745;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Form <FONT STYLE="white-space:nowrap">40-F&nbsp;&nbsp;&nbsp;&#9744;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT
STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&nbsp;&nbsp;&nbsp;&#9744; </P> <P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On December&nbsp;1, 2022, Kazia Therapeutics Limited (the &#147;Company&#148;) issued an ASX announcement titled, &#147;Compelling
Preclinical Data for Kazia&#146;s EVT801 Published in Peer-Reviewed Cancer Research Journal.&#148; A copy of this release is attached hereto as Exhibit&nbsp;99.1 and is incorporated herein by reference. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quotes of
Dr.&nbsp;Michael Paillasse, Professor Jean-Pierre Delord, and Dr.&nbsp;James Garner contained in Exhibit 99.1, into the Company&#146;s registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-259224).</FONT> </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Description</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d418328dex991.htm">ASX Announcement of Kazia Therapeutics Limited dated December&nbsp;1, 2022 </A></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"><B>Kazia Therapeutics Limited</B> (Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Karen Krumeich</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Karen Krumeich</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Financial Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: 1&nbsp;December 2022</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d418328dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g418328dsp3a.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">ASX ANNOUNCEMENT </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1&nbsp;December 2022 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>COMPELLING PRECLINICAL
DATA FOR KAZIA&#146;S EVT801 PUBLISHED IN PEER-REVIEWED CANCER RESEARCH JOURNAL </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Sydney, 1</B><B></B><B>&nbsp;December 2022</B> &#150; Kazia
Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce the publication of positive preclinical data for EVT801, a clinical-stage drug candidate currently in a clinical trial for multiple
forms of cancer. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The publication, by Michael Paillasse and colleagues, summarizes a large body of preclinical research conducted principally by
scientists at Evotec SE and at the University Cancer Institute of Toulouse - Oncopole over a period of several years. It is now published in <I>Cancer Research Communications</I>, a recently-launched journal published by the American Association of
Cancer Research (AACR). The data formed the basis of Kazia&#146;s <FONT STYLE="white-space:nowrap">in-licensing</FONT> of EVT801 from Evotec in 2021 and has since supported transition of the compound into an ongoing phase I clinical trial in
patients with advanced solid tumors. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Key Points </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EVT801 is a selective inhibitor of vascular endothelial growth factor receptor 3 (VEGFR3). VEGFs and VEGFRs are
well-validated cancer drug targets with multiple <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products directed to them, but a more selective VEGFR3 inhibitor, such as EVT801, may result in better tolerability and less development of
resistance to therapy. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EVT801 was confirmed in preclinical studies to be a potent and selective inhibitor of VEGFR3, with activity in
the low nanomolar range. The drug was shown to inhibit the formation of lymphatic vessels <I>in vitro</I>, confirming its intended primary mode of action. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt"><I>In vivo </I>(animal) experiments showed EVT801 to be more active than both pazopanib (Votrient<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Novartis) and sorafenib (Nexavar<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Bayer) in the tumor models under investigation. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">EVT801 combined with immune checkpoint inhibitors in mouse models of several tumor types showed strongly
synergistic activity, with the combination performing better than either drug alone. Immune checkpoint inhibitors are widely used in many cancers, and the class includes drugs such as pembrolizumab (Keytruda<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Merck), nivolumab (Opdivo<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>, Bristol Myers Squibb), and ipilimumab (Yervoy<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP>,
Bristol Myers Squibb). </P></TD></TR></TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;These data demonstrate the substantial potential of EVT801 as a cancer therapeutic,&#148; stated Dr
Michael Paillasse, lead author of the publication. &#147;EVT801 has been shown to act exactly as intended: by impacting the vasculature in and around the tumor. In addition, the evidence of synergy with immunotherapy is persuasive, and we see a
considerable opportunity to combine the drug with immune checkpoint inhibitors in clinical trials.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are grateful that the results of this
public-private translational research initiative have been appreciated by the editors and reviewers of <I>Cancer Research Communications.</I> We will now focus on the clinical development,&#148; said Professor Jean-Pierre Delord, <FONT
STYLE="white-space:nowrap">co-author</FONT> and CEO of the IUCT &#150; Oncopole. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#147;We are delighted to see this exciting and comprehensive body of
work now published in a leading peer-reviewed journal,&#148; said Dr James Garner, Chief Executive Officer of Kazia. &#147;The data supports our decision last year to <FONT STYLE="white-space:nowrap">in-license</FONT> EVT801, and clearly points to
the future development strategy for the drug. Our collaboration with the Evotec team has already been extremely fruitful, and we look forward to continuing to work together on this very promising drug candidate.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The publication may be accessed via the journal website at
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">https://aacrjournals.org/cancerrescommun/article/2/11/1504/711325/Targeting-Tumor-Angiogenesis-with-the-Selective.</FONT></FONT> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Phase I Clinical Trial Progressing </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">EVT801 is currently
the subject of an ongoing phase I clinical trial as monotherapy in patients with advanced solid tumors (NCT05114668). The study is progressing as planned, with patients currently being dosed within the anticipated therapeutic range. It is expected
that initial data from this study will be available in 1H CY2023. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For More Information, Please Contact:- </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jane Lowe </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">IR Department </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">jane.lowe@irdepartment.com.au </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Phone: +61 411 117 774 </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an oncology-focused drug development company, based in Sydney, Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our lead program is paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer.
Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this disease. A completed phase II study in glioblastoma reported promising signals of efficacy in 2021, and a pivotal study for registration, GBM
AGILE, is ongoing, with final data expected in CY2023. Other clinical trials are ongoing in brain metastases, diffuse midline gliomas, and primary CNS lymphoma, with several of these having reported encouraging interim data. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Paxalisib was granted Orphan Drug Designation for glioblastoma by the US FDA in February 2018, and Fast Track Designation for glioblastoma by the US FDA in
August 2020. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Designation by the US FDA for DIPG in August 2020, and for atypical teratoid / rhabdoid tumours (AT/RT) in June 2022 and July 2022, respectively. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is also developing EVT801, a small-molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided compelling evidence of synergy with immuno-oncology agents. A phase I study commenced recruitment in November 2021. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information, please visit www.kaziatherapeutics.com or follow us on Twitter @KaziaTx. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About IUCT-Oncopole </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The IUCT-Oncopole, a cancer care,
research and training center in Toulouse, combines the expertise of 1,800 professionals on a single site labeled &#147;Comprehensive Cancer Center&#148;. It combines several <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">state-of-the-art</FONT></FONT></FONT> clinical facilities for the treatment of cancer with a world-class research infrastructure, on an integrated campus that brings together public and private stakeholders, including
industrial partners. The IUCT-Oncopole, which includes the Claudius Regaud Institute (ICR) and several teams from the Toulouse University Hospital, treats more than 10,000 new patients every year, and more than one in eight patients is enrolled in
clinical studies. Visit https://news.iuct-oncopole.fr/ for more. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This document was authorized for release to the ASX by James Garner, Chief Executive
Officer, Managing Director. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#147;may,&#148;
&#147;will,&#148; &#147;estimate,&#148; &#147;future,&#148; &#147;forward,&#148; &#147;anticipate,&#148; or other similar words. Any statement describing Kazia&#146;s future plans, strategies, intentions, expectations, objectives, goals or
prospects, and other statements that are not historical facts, are also forward-looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia&#146;s clinical and preclinical trials, and
Kazia&#146;s strategy and plans with respect to its programs, including paxalisib and EVT801. Such statements are based on Kazia&#146;s expectations and projections about future events and future trends affecting its business and are subject to
certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties: associated with clinical and preclinical trials and product
development, related to regulatory approvals, and the related to the impact of global economic conditions. These and other risks and uncertainties are described more fully in Kazia&#146;s Annual Report, filed on form
<FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the SEC. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise,
except as required under applicable law. You should not place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g418328dsp3a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g418328dsp3a.jpg
M_]C_X  02D9)1@ !  $ 8 !@  #__@ ?3$5!1"!496-H;F]L;V=I97,@26YC
M+B!6,2XP,0#_VP"$  @&!@<&!0@'!P<*"0@*#18.#0P,#1L3%! 6(!PB(1\<
M'QXC*#,K(R8P)AX?+#TM,#4V.3HY(BL_0SXX0S,X.3<!"0H*#0L-&@X.&C<D
M'R0W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W-S<W
M-S<W-S<W-__$ :(   $% 0$! 0$!           ! @,$!08'" D*"P$  P$!
M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * %1'D<)
M&I=SP%49)H2OL)M)78Z6"6"3RYHGC?\ NNI!IM-:,(R4E=,=-:W%N%,\$D0;
M[N]2,_G0XM;H49QE\+N14B@H * "@ H * "@ H * "@ H * "@ H * "@ H
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M#AAZTU)/03BT8M42% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
M % &WX:TNUU.[E6Y)*QKD(#C=6U&"F]3CQ=:5**<2VWV/PUXG! 9X#'TZF//
M_P"K\C5^[2J&:Y\50\_S(]9UVUN]6LKB"(O';-DEA@OR#C]*52JI2370=##S
MA3E&3W)O$.OV6I6$=O;ABQ<,69<;:=6K&<;(G"X:=*;E(FU7PYI]GHC7$3L)
M8U!#ELA_PJJE&,871%'%5)U>5['(UR'J!0 4 % !0 4 % !0 >PH * "@ H
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M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M61X)72<X4 >E?!_P]]NUF;69TS#9#;'D<&0C^@_F*RJ2LK&M-:W,+XC>'O\
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M 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 /,TK6Z0%R8D8NJ=@2 "?\
MQT?E0 R@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M3G^R!IWRJ^>?E7H!T[#%:*<4K&3A)NYYE+$T,SQ/PR,5/U%;&19TK_D,6/\
MUW3_ -"%)[#6Y[G\7?\ D17_ .OB/^M<]/XC>I\)X#72<YWOPH\/?VKXF_M"
M9,VVG@2<C@R'[H_#D_@*RJ.RL:4U=W/6O$,OA34!_9VNWMD?)8.89;G85.."
M0".Q_6L8\RU1L^5Z,LZ,WA^736TK2+BUGM(D*M#%,) JMG@\DX/-#O>[&K;(
M^=_%.AOX=\1WFFMG9&^8F/\ $AY4_E^M=,7=7.:2L[&/5$A0 4 % !0 4 %
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MN*L<[J%]+J6I7-].%$MQ*TKA1@ DY.*I*RL2W=W.PL/BQXBL-/AL]MI.L2;
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M:7,ZF2% !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
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MVMQ4TUC:K/+<0P"0$QK(3EP/H./QH4-+MB=5*7*DV(=/9+!+MYHD#@E$.=S
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
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M !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0
M4 % !0 4 *CO&X>-V1AT*G!%"=MA-)JS+FFZG-IM^+M1YC8(8,?O ^]7";A*
MYE5HJK#D+6I>()]0O;>X6-8OLYW(N<\Y!Y_(54ZKDT^QG2PT:<7&][DFK>))
MM4LUMC L2Y!8@YSC^5.I6<U8FAA(T9<U[F,9'9 A=B@Z*3P*QN==DG<;0,*
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "
M@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
M H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@
MH * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H *
M"@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
K * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H * "@#_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
